Enhancement of paclitaxel activity against hormone-refractory prostate cancer cells in vitro and in vivo by quinacrine

British Journal of Cancer

Volumn 75, Issue 11, 1997, Pages 1593-1600

  De Souza, P L ^a   Castillo, M ^a,b   Myers, C E ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b NONE   (United States)

Author keywords

Chou analysis; Dose response; Interaction; Ras signalling; Synergy; Xenografts

Indexed keywords

ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEPACRINE; MEVINOLIN; PACLITAXEL; PHOSPHOLIPASE A2 INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER MODEL; CELL VIABILITY; DRUG POTENTIATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; TUMOR XENOGRAFT;

EID: 0030915889     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.272     Document Type: Article

References (33)

1. Babb RR (1995) Giardiasis. Taming this pervasive parasitic infection. Postgrad Med 98: 155-158
2. 2: function and pharmacological regulation. Biochem Pharmacol 36: 2429-2436
3. Chou JH (1991) Quantitation of synergism and antagonism of two or more drugs by computerized analysis. In Synergism and Antagonism in Chemotherapy. Chou TC and Rideout DC (eds), pp. 223-241. Academic Press: San Diego
4. Chou TC and Talalay P (1977) A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 252: 6438-6442
5. Chou TC and Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55
6. Chou J and Chou TC (1987) Dose Effect with Microcomputers. Manual and Software for IBM-PC. Biosoft: Cambridge, UK
7. Chou TC, Tan QH and Sirotnak FM (1993) Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro. Cancer Chemother Pharmacol 31: 259-264
8. Chou TC, Motzer RJ, Tong Y and Bosl GJ (1994) Computerized quantitation of synergism and antagonism of paclitaxel, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517-1524
9. Danesi R, Figg DW, Reed E and Myers CE (1995) Paclitaxel (Taxol®) inhibits isoprenylation and induces apoptosis in PC-3 human prostate cancer cells. Mol Pharmacol 47: 1106-1111
10. 1 mice. Cancer Chemother Pharmacol 34: 465-171
11. Fenton RG, Kung HF, Longo DL and Smith MR (1992) Regulation of intracellular actin polymerization by prenylated cellular proteins. J Cell Biol 117: 347-356
12. Ford JM, Prozialeck WC and Hait WN (1989) Structural features determining activity of phenothiazines and related drugs for inhibition of cell growth and reversal of multidrug resistance. Mol Pharmacol 35: 105-115
13. Hanada K, Kinoshita E, Itoh M, Hirata M, Kajiyama G and Sugiyama M (1995) Human pancreatic phospholipase A, stimulates the growth of human pancreatic cancer cell line. FEBS Lett 373: 85-87
14. Hohl RJ and Lewis K (1995) Differential effects of monoterpenes and lovastatin on RAS processing. J Biol Chem 270: 17508-17512
15. Heitjan DF, Manni A and Santen RJ (1993) Statistical analysis of in vivo tumor growth experiments. Cancer Res 53: 6042-6050
16. Hudes GR, Nathan FE, Khater C, Greenberg R, Gomella L, Stern C and McAleer C (1995) Paclitaxel plus estramustine in metastatic hormone-refractory prostate cancer. Semin Oncol 22 (suppl. 12): 41-15
17. Isaacs WB, Morton RA, Bussemakers MJG, Brooks JD and Ewing CM (1994) Molecular biology of prostate cancer. Semin Oncol 21: 514-521
18. 2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 33: 48-52
19. Khosravi-Far R and Der C (1994) The Ras signal transduction pathway. Cancer Metast Rev 13: 67-89
20. 2 is phosphorylated and activated by MAP kinase. Cell 72: 269-278
21. 2 in malignant and non-malignant human gastric mucosa. Br J Cancer 68: 103-111
22. Ogiso Y, Sakai N, Watari H, Yokoyama T and Kuzumaki N (1994) Suppression of various human tumor cell lines by a dominant negative H-ras mutant. Gene Therapy 1: 403-407
23. Pretlow TG, Delmoro CM, Dilley GG, Spadafora CG and Pretlow TP (1991) Transplantation of human prostatic carcinoma into nude mice in matrigel. Cancer Res 51: 3814-3817
24. Ruch RJ, Madhukar BV, Trosko JE and Klaunig JE (1993) Reversal of ras-induced inhibition of gap-junctional intercellular communication, transformation, and tumorigenesis by lovastatin. Mol Carcinogenesis 7: 50-59
25. Schiff P, Fant J and Horwitz S (1979) Promotion of microtubule assembly in vitro by Taxol. Nature 277: 665-667
26. Schiff P and Horwitz SB (1980) Taxol stabilizes microtubules in mouse fibroblast cells, Proc Natl Acad Sci USA 77: 1561-1565
27. Seigsmund MJ, Cardarelli C, Aksentijevich I, Sugimoto Y, Pastan I and Gottesman MM (1994) Ketoconazole effectively reverses multidrug resistance in highly resistant KB cells. J Urol 151: 485-491
28. Shannon JA, Earle DP, Brodie BB, Taggart JV and Berliner RW (1944) The pharmacological basis for the rational use of atabrine in the treatment of malaria. J Pharmacol Exp Ther 81: 307-330
29. 2-induced stimulation of A549 lung adenocarcinoma cell line proliferation. Biochim Biophys Acta 1164: 236-242
30. H expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells. Mol Endocrinol 5: 209-216
31. Wallace DJ (1994) Antimalarial agents and lupus. Rheum Dis Clin N Am 20: 243-263
32. 2 in human breast cancer tissues is closely associated with their malignant potency. Br J Cancer 69: 1166-1170
33. Zidovetzki R, Sherman IW, Maguire PA and De Boeck H (1990) A nuclear magnetic resonance study of the interactions of the antimalarials chloroquine, quinacrine and mefloquine with lipids extracted front normal human erythrocytes. Mol Biochem Parasitol 38: 33-40